Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Clin Immunol. 2018 Mar 21;192:6–13. doi: 10.1016/j.clim.2018.03.010

Figure 3.

Figure 3

Toxicity Percentage of patients in each group experiencing maximum toxicities of each grade. There were no grade 3 or higher toxicities experienced by any patient. There were no significant differences in maximum toxicities between groups based on dosing or vaccine sequence.